Affordability is about predictable total cost and what's bundled — not just the lowest sticker. Here's how to get the best value on tirzepatide.
"Affordable" is about predictable total cost and what's included, not just the lowest sticker. Here's how to maximize value.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| NexLife Editor's pick | Flat-rate, bundled, HSA/FSA | $186/mo* | Not FDA-approved |
| Other compounded programs | Varies (check inclusions) | $209–$400/mo | Not FDA-approved |
| Zepbound® LillyDirect self-pay | Brand, medication only | $299–$449/mo | FDA-approved |
Flat dose-independent pricing, bundled visits and labs, HSA/FSA eligibility, and plan-term flexibility all lower your real cost. Compounded tirzepatide is not FDA-approved. See NexLife pricing
Some programs offer financing to spread payments; terms vary by provider. HSA/FSA funds are commonly accepted for cash-pay programs.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.